AeroLeads people directory · profile

Peter G. Linde, Md, Fasn Email & Phone Number

Vice President at Thermo Fisher Scientific
Location: Greater Boston, United States, United States 10 work roles 4 schools
1 work email found @acceleronpharma.com 3 phones found area 617 LinkedIn matched
✓ Verified May 2026 4 data sources Profile completeness 100%

Contact Signals · 1 work email · 3 phones

Work email p****@acceleronpharma.com
Direct phone (617) ***-****
LinkedIn Profile matched
3 free lookups remaining · No credit card
Current company
Role
Vice President
Location
Greater Boston, United States, United States

Who is Peter G. Linde, Md, Fasn? Overview

A concise factual answer block for searchers comparing this professional profile.

Quick answer

Peter G. Linde, Md, Fasn is listed as Vice President at Thermo Fisher Scientific, based in Greater Boston, United States, United States. AeroLeads shows a work email signal at acceleronpharma.com, phone signal with area code 617, and a matched LinkedIn profile for Peter G. Linde, Md, Fasn.

Peter G. Linde, Md, Fasn previously worked as Chief Medical Officer at Walden Biosciences and Chief Medical Officer at Morphic Therapeutic. Peter G. Linde, Md, Fasn holds Medical Doctor, Medicine from Stanford University School Of Medicine.

Company email context

Email format at Thermo Fisher Scientific

This section adds company-level context without repeating Peter G. Linde, Md, Fasn's masked contact details.

*@acceleronpharma.com
68% confidence

AeroLeads found 1 current-domain work email signal for Peter G. Linde, Md, Fasn. Compare company email patterns before reaching out.

Profile bio

About Peter G. Linde, Md, Fasn

Experienced medical professional with a successful track record in the biopharmaceutical industry. Skilled in research and development (R&D), U.S. Food and Drug Administration (FDA), clinical research, life sciences, and translational medicine. Graduate of the Stanford School of Medicine and Massachusetts Institute of Technology. Strong clinical development leader leading teams in strategy/execution of high-value clinical development programs for biotech companies leading to 4 global regulatory approvals and 2 company acquisitions.

Listed skills include Clinical Development, Clinical Trials, Pharmaceutical Industry, Clinical Research, and 25 others.

Current workplace

Peter G. Linde, Md, Fasn's current company

Company context helps verify the profile and gives searchers a useful next step.

Thermo Fisher Scientific
Thermo Fisher Scientific
Vice President
AeroLeads page
10 roles

Peter G. Linde, Md, Fasn work experience

A career timeline built from the work history available for this profile.

Vice President

Current

Waltham, MA, US

Within the biotech solutions business I reach out to and work with commercial customers to help optimize the clinical research, development and manufacturing, and clinical logistics capabilities we bring to bear in order to serve our biotech customers even more effectively.Our clients turn to us to streamline their path to commercialization, and we’re.

Jul 2024 - Present

Chief Medical Officer

Cambridge, MA, US

  • Led clinical group to drive clinical/regulatory development strategy across new therapeutics under development, including hiring/optimizing team performance.
  • Created clinical/regulatory strategic plans for/led filing of first Walden IND (WAL0921, anti-suPAR mab), was accepted via a Study May Proceed Letter from FDA, leading to Phase 1 SAD study.
  • Mapped out complete clinical/regulatory development strategies, including trial designs, timelines, team hiring plans, and estimated costs for two programs' Phase 1, 2, and 3 development.
Oct 2022 - Sep 2023

Chief Medical Officer

Waltham, MA, US

  • Built out/led clinical group to drive clinical and regulatory development across entire small molecule integrin inhibitor pipeline. Hired clinical operations/data management group, GI-MD, clinical science, and.
  • Led first IND (MORF-O57) resulting in acceptance without comment from FDA.
  • Initiated first Phase 1 SAD/MAD/FE Trial of MORF-057 in healthy volunteers and two studies, drove creation of Phase 2 and 3 clinical development programs in UC and Crohn's Disease: POC design for PSC.
  • Partnered with executive leadership team to speak with investor community to discuss data; stock realized 150%+ increase in value on release of Phase 1 topline.
Mar 2020 - Dec 2021

Vice President, Medical Research

Cambridge, MA, US

  • Led pharmacovigilance, medical affairs, clinical science, clinical pharmacology, and biometrics.
  • Took over Sotatercept, which was underperforming—spearheaded phase 2 POC development within Pulmonary Arterial Hypertension, which led to Merck's $11B acquisition.
  • Advanced Luspatercept through Phase 2 and 3 development/worked with team/Celgene to secure FDA/EMA approvals in 2 indications: B-thalassemia and Myelodysplastic syndrome.
  • Led Phase 3 COMMANDS Trial in E.S.A. Naïve M.D.S. Patients/Phase 2 MPN-associated Myelofibrosis and Phase 2 Non-Transfusion Dependent B-Thalassemia (BEYOND) studies.
Jul 2016 - Feb 2020

Global Project Leader, Development

North Chicago, Illinois, US

  • Led global asset development teams for three products in renal/immunology development and collaborated with two public/private partnerships.
  • Partnered with regulatory team to gain approval for Zemplar in China. Built/submitted data package and presented to local affiliates. Led to brand approval in 2013.
  • Led authorship of white paper on Barriers and Solutions for Enhancing Innovation in Nephrology, published in JASN 2016.
  • Spearheaded EU Innovative Medicine Initiative for BeatDKD's five-year, $ 30MM project, which included collaboration with 18 EU/US academic institutions and eight industry partners.
Sep 2011 - Jun 2016

Senior Director, Clinical Research

San Francisco, CA, US

  • Led US Phase 1b and Phase 2a trials to advance FG-4592 for Anemia in ESRD patients receiving hemodialysis.
  • Led US Phase 2b Anemia in hemodialysis and contributed to China Phase 2 anemia in CKD/pre-dialysis and ESRD hemodialysis.
Mar 2010 - Sep 2011

Clinical Assistant Professor Of Medicine

San Francisco, California, US

Attending physician- provided basic/subspecialty care to native and transplanted kidney patients.

Sep 2006 - Aug 2011

Clinical Consultant

Peter G Linde Consulting
  • Gilead Sciences, Inc.
  • Completed clinical adjudication committee charter for Darusentan Phase 3.
  • Authored white paper on Darusentan and endothelin-a antagonist effects on renal function in subjects with hypertension and proteinuric nephropathy.Cardio Dx Inc.
  • Completed two versions of Compass protocol, a post-510(k) approval trial to assess diagnostic performance of blood-based gene test concerning myocardial perfusion imaging for assessing CAD risk, including DSMB charter.
  • Completed methods/rationale manuscript for PREDICT trial, the pre-510(k) approval trial for blood-based gene test for assessing significant CAD risk. Portola Pharmaceuticals Inc.
  • Medical monitor for Elinogrel Phase 2 trial: ERASE-MI
Apr 2008 - Dec 2009

Co-Founder & President

Triaxis Medical Devices, Inc.
  • President/Co-Founder/CMO
  • Filed multiple patent applications with USPTO, completed series A funding, prototyped/constructed devices, and completed initial benchtop testing.
Jan 2008 - Dec 2009

Director, Clinical Research

New Brunswick, NJ, US

  • Led Phase 2 and 3 trials to develop two new indications for Natrecor.
  • UNOS 1b candidates awaiting cardiac transplantation (Phase 2).
  • Post MVR/CABG on CPB patients (Phase 2 and 3).
  • Acute decompensated heart failure (Phase 3).
Jun 2005 - Jan 2008
4 education records

Peter G. Linde, Md, Fasn education

Medical Doctor, Medicine

Stanford University School Of Medicine

Two Fellowships At Massachusetts General Hospital, Nephrology And Medical Transplantation

Harvard Medical School

Internship& Residency, Internal Medicine

University Of Pennsylvania School Of Medicine

S.B., Chemical Engineering And Applied Biology

Massachusetts Institute Of Technology
FAQ

Frequently asked questions about Peter G. Linde, Md, Fasn

Quick answers generated from the profile data available on this page.

What company does Peter G. Linde, Md, Fasn work for?

Peter G. Linde, Md, Fasn works for Thermo Fisher Scientific.

What is Peter G. Linde, Md, Fasn's role at Thermo Fisher Scientific?

Peter G. Linde, Md, Fasn is listed as Vice President at Thermo Fisher Scientific.

What is Peter G. Linde, Md, Fasn's email address?

AeroLeads has found 1 work email signal at @acceleronpharma.com for Peter G. Linde, Md, Fasn at Thermo Fisher Scientific.

What is Peter G. Linde, Md, Fasn's phone number?

AeroLeads has found 3 phone signal(s) with area code 617 for Peter G. Linde, Md, Fasn at Thermo Fisher Scientific.

Where is Peter G. Linde, Md, Fasn based?

Peter G. Linde, Md, Fasn is based in Greater Boston, United States, United States while working with Thermo Fisher Scientific.

What companies has Peter G. Linde, Md, Fasn worked for?

Peter G. Linde, Md, Fasn has worked for Thermo Fisher Scientific, Walden Biosciences, Morphic Therapeutic, Acceleron Pharma, and Abbvie.

How can I contact Peter G. Linde, Md, Fasn?

You can use AeroLeads to view verified contact signals for Peter G. Linde, Md, Fasn at Thermo Fisher Scientific, including work email, phone, and LinkedIn data when available.

What schools did Peter G. Linde, Md, Fasn attend?

Peter G. Linde, Md, Fasn holds Medical Doctor, Medicine from Stanford University School Of Medicine.

What skills is Peter G. Linde, Md, Fasn known for?

Peter G. Linde, Md, Fasn is listed with skills including Clinical Development, Clinical Trials, Pharmaceutical Industry, Clinical Research, Fda, Biotechnology, Clinical Study Design, and Drug Development.

Find 750M verified contacts

Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.